Chemical Information | |
Antiviral agent ID | DrugRepV_4787 | |
Antiviral agent name | 2-(5-{[(4Z)-1-(3-carboxyphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid | |
IUPAC Name | 2-(5-{[(4Z)-1-(3-carboxyphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid | |
SMILES (canonical) | OC(=O)C1=CC(=CC=C1)N1N=C(\C(=C\C2=CC=C(O2)C2=CC(Cl)=CC=C2C(O)=O)C1=O)C1=CC=CC=C1 | |
Molecular Formula | C28H17ClN2O6 | |
Molecular Weight (g/mol) | 512.9 | |
InChl | InChI=1S/C28H17ClN2O6/c29-18-9-11-21(28(35)36)22(14-18)24-12-10-20(37-24)15-23-25(16-5-2-1-3-6-16)30-31(26(23)32)19-8-4-7-17(13-19)27(33)34/h1-15H,(H,33,34)(H,35,36)/b23-15- | |
Structural Information | |
|
|
Clinical Information | |
Biological Information | |
Secondary Indication | Severe acute respiratory syndrome coronavirus (SARS-CoV) NA NA | |
Secondary Indication (Approaches) | Experimental | |
Secondary Indication (Methods) | In-vitro | |
Secondary Indication (Drug concentration) | 44.7 ± 5.1 μM
| |
Secondary Indication (Change) | Decrease
| |
Secondary Indication (Type of Inhibition) | IC50 [ 50 % ] | |
Reference | Kumar V, Tan KP, Wang YM, Lin SW, Liang PH..Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors..Bioorg Med Chem. 2016 Jul 1;24(13):3035-3042. doi: 10.1016/j.bmc.2016.05.013. Epub 2016 May 12. PMID:27240464
| |
Comment | Docking studies show that a carboxylate present at either R1 or R4 destabilizes the oxyanion hole in the 3CLpro. Compounds 3f, 3g and 3m could inhibit both NA and 3CLpro and serve as a starting point to develop broad-spectrum antiviral agents.
| |